Fig. 7.

LOXL2 inhibits the tumor growth of gemcitabine-resistant pancreatic cancer cells and increases sensitivity to gemcitabine. A WST-1 assay of Mia con and Mia GR (control, LOXL2 siRNA transfection) cells exposed to gemcitabine at different concentrations for 48 h. B Scheme of cell administration into the flanks of a nude mouse. C Tumor volumes of Mia Con and Mia GR (control, LOXL2 shRNA transfected) administered mouse were measured every 3 days. D Representative tumor bearing mouse image. E Images of the tumors harvested from mice on day 35. F Mouse tumor wet weights on day 35 after tumor inoculation. G Scheme of gemcitabine intraperitoneal injection to tumor bearing mouse. (100 mg/kg) H Tumor volumes of Mia con and Mia GR (control, LOXL2 shRNA transfected) administered and gemcitabine treated mice were measured every three days. I Representative tumor bearing mouse image. J Images of tumors harvested from mice on day 42. K Tumor wet weights of the mouse on day 42 after gemcitabine I.P. injection